Suzhou Wulian Medical Technology Co., Ltd. has recently finalized a Series B funding round, raising tens of millions of yuan. This round was spearheaded by Zhenhua, with additional investment from the Kunshan Yujian Weilai Fund. The capital infusion will be predominantly allocated towards refining core technologies, expanding production capacity, and accelerating global market penetration. As a trailblazer in China's micro-mesh nebulization technology landscape, Wulian Medical has erected formidable technological barriers on a global scale. It has introduced a diverse range of differentiated products tailored for hospital, home-use, and overseas ICU markets. Notably, several of its offerings have shattered overseas monopolies, with the performance of their core components achieving international benchmarks. The company is also vigorously exploring avant-garde nebulization application domains, establishing a sophisticated pharmaceutical-device joint operation service framework, and forging deep-rooted partnerships with numerous prominent domestic and international pharmaceutical entities. Several collaborative projects have progressed to Phase II and III clinical trials. With the completion of this funding round, Wulian Medical is poised to ramp up investments in core technology R&D, intelligent manufacturing capabilities, and global market outreach.